AbbVie Inc (ABBV)vsAlpha Cognition Inc (ACOG)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
ACOG
Alpha Cognition Inc
$5.87
-5.32%
HEALTHCARE · Cap: $127.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 598317% more annual revenue ($61.16B vs $10.22M). ABBV leads profitability with a 6.9% profit margin vs -202.2%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ACOG
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for ACOG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -40.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ACOG
The strongest argument for ACOG centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ACOG
The primary concerns for ACOG are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while ACOG is a turnaround play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.52 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 22/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is an innovative biopharmaceutical firm focused on developing advanced therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its flagship product, ACOG-100, aims to improve cognitive function and fulfill critical unmet medical needs among the aging population. Leveraging a proprietary neuroscience platform and a comprehensive R&D strategy, the company is poised to make significant strides in patient care. As Alpha Cognition progresses with its clinical pipeline and explores new therapeutic options, it presents an appealing investment opportunity for institutional investors seeking to engage with the transformative healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?